| |
Douglas M. Fambrough, Ph.D.
General Partner
Boston, MA
dfambrough@oxbio.com |
Since joining Oxford in 1999, Dr. Fambrough has specialized in financing innovative life science technology companies. His current projects include Dicerna Pharmaceuticals, a second generation “RNA Interference” company co-founded by Dr. Fambrough; Cambrios Technologies, which invented and now markets biologically-inspired electronic materials for touch screens, flat panel displays, and photovoltaics; Xencor, a protein engineering company that engineers antibody Fc regions to enhance drug potency; Rib-X Pharmaceuticals, a developer of antibiotics against multi-drug resistant pathogens; and Solstice Neurosciences, which markets the protein drug Myobloc for movement disorders. His past investments include RNA Interference pioneer Sirna Therapeutics, acquired by Merck for $1.1 billion, and the ultra-high-throughput DNA sequencing equipment company Solexa, acquired by Illumina for $600 million. Prior to Oxford, Dr. Fambrough was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute). He graduated from Cornell University and obtained his Ph.D. in genetics from the University of California, Berkeley.
Back to OBP Team
|
|